ROMEG Therapeutics' autumn daffodil oral liquid GLOPERBA obtains FDA approval

acute gout is a common and complex form of arthritis caused by excessive uric acid production or poor uric acid excretionThe most common pathogenesis of acute gout is in the big toe, where some patients describe gout attacks like a big toe being burnedrecently, ROMEGSPharmaceutical(http://company(http://developed the autumn daffodil oral liquid GLOPERBA has been approved by the U.SFood andMedicines(http://Administration (
FDA(http://this is the first FDA-approved oral solution for the treatment of acute goutautumn daffodilis is a common lying drug for acute gout, and the u.Smarket for autumn daffodils is currently about $800 million Autumn daffodils can inhibit the concentration of white blood cells in the inflamed area, so that the role of white blood cells to swallow uric acid is reduced, reduce the response of acute gout, to achieve rapid pain relief purposes 　　However, autumn daffodils can have side effects on the internal organs, and doctors who use autumn daffodils to treat acute gout often need to adjust the dose or interrupt the patient's treatment to address the interaction of the drug with other treatments, such as kidney dialysis How to adjust the dose of autumn daffodils to meet the needs of patients with gout with kidney and liver damage is a problem that needs to be solved urgently ROMEG Therapeutics solves this problem by developing GLOPERBA oral fluids that make it easy for doctors to adjust patient doses compared to existing autumn daffodil capsules on the market , about 15 percent of older patients in the U.S have difficulty swallowing and can't swallow solid pills, and GLOPERBA oral fluids make it easy for them to take the drug